Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.

O'Neil, Patrick M et al.·Postgraduate medicine·2022·
RPEP-064032022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Semaglutide 2.4 mg significantly improved quality of life scores and reduced total fat mass compared to placebo.

Key Numbers

How They Did This

The study analyzed data from the STEP trials, comparing semaglutide 2.4 mg with placebo in adults with obesity, assessing quality of life and body composition.

Why This Research Matters

Understanding the broader benefits of semaglutide can help healthcare providers make informed decisions about obesity treatment options, improving patient outcomes.

What This Study Doesn't Tell Us

The study primarily focuses on specific subgroups and may not represent all patients with obesity.

Trust & Context

Original Title:
Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.
Published In:
Postgraduate medicine, 134(sup1), 28-36 (2022)
Database ID:
RPEP-06403

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-06403·https://rethinkpeptides.com/research/RPEP-06403

APA

O'Neil, Patrick M; Rubino, Domenica M. (2022). Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.. Postgraduate medicine, 134(sup1), 28-36. https://doi.org/10.1080/00325481.2022.2150006

MLA

O'Neil, Patrick M, et al. "Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.." Postgraduate medicine, 2022. https://doi.org/10.1080/00325481.2022.2150006

RethinkPeptides

RethinkPeptides Research Database. "Exploring the wider benefits of semaglutide treatment in obe..." RPEP-06403. Retrieved from https://rethinkpeptides.com/research/o-neil-2022-exploring-the-wider-benefits

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.